Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Verastem Joins The Public Markets With A Strong IPO

This article was originally published in The Pink Sheet Daily

Executive Summary

Verastem IPO’d at $10 per share on Jan. 26, despite having only preclinical assets in its pipeline. Strong interest from large companies for cancer stem cell therapies helped contribute to the price.

Advertisement

Related Content

Ambit IPO Ambles Out; Portola And Bluebird Prepare
Biopharma IPOs Start to Gear Up For 2013 After a Lull
Biopharma IPOs Start To Gear Up For 2013 After A Lull
More And Better Biotech IPOs, But Step-Ups Still Lag
Verastem Catapults To Mid-stage Development with Pfizer Licensing Deal
Start-Up Quarterly Statistics, Q1 2012
Biopharma Quarterly Deal Statistics, Q1 2012
Glaxo Shifts Rx Resveratrol Focus But Nutritional Interest Still Strong
OncoMed Signs Second Cancer Stem Cell Partner; This Time It's Bayer
Taking Aim At Recurrence: Targeting Cancer Stem Cells To Stop Proliferation

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073314

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel